On the contrary, CCL20 deficiency counteracted the increased population of CCR6+ CD8+ T cells and attenuated the anticancer effect of the combined treatment of ICB and EPS-R1 in tumor-bearing mice. The gene discussed is CD8A; the disease is neoplasm.